Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Phase 2 Recruiting 30 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.

Timeline

Start: 2024-08-01
Primary completion: 2028-12
Completion: 2029-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	—
Subject	Sonrotoclax	Other / unclassified	320 mg	Oral
Subject	Zanubrutinib	Small molecule	320 mg	Oral

Indications

No indication recorded.